Literature DB >> 3167782

Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides.

M A Weinstock1, J W Horm.   

Abstract

Mycosis fungoides is the most common cutaneous lymphoma in the US, and it is increasing rapidly in both incidence and mortality. Our knowledge of its prognosis derives primarily from case series, which are subject to possible selection bias and other limitations. The current analysis examines trends in survival and prognostic factors in data from nine population-based cancer registries in the US. Among the 650 cases followed with known dates of diagnosis and no history of prior malignancy, the median survival time was 7.8 years. Advanced age, black race, prior malignancy, and Sezary syndrome presence at the time of diagnosis were each independently associated with poor prognosis. Fatality was not influenced by sex or geographic area. There was no consistent evidence of improved survival with time over the 12-year study period.

Entities:  

Mesh:

Year:  1988        PMID: 3167782     DOI: 10.1002/1097-0142(19881015)62:8<1658::aid-cncr2820620834>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Consistency and distribution of reflectance confocal microscopy features for diagnosis of cutaneous T cell lymphoma.

Authors:  Susanne Lange-Asschenfeldt; Jasmin Babilli; Marc Beyer; Francisca Ríus-Diaz; Salvador González; Eggert Stockfleth; Martina Ulrich
Journal:  J Biomed Opt       Date:  2012-01       Impact factor: 3.170

2.  Extracorporeal photophoresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-03-01

Review 3.  Cutaneous T-cell lymphoma/leukemia.

Authors:  R S Siegel; T M Kuzel
Journal:  Curr Treat Options Oncol       Date:  2000-04

4.  Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.

Authors:  B Prinz; W Behrens; E Hölzle; G Plewig
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.